Related Experiment Video
Updated: Jun 27, 2025

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle
Published on: March 5, 2019
DNA-PK participates in pre-rRNA biogenesis independent of DNA double-strand break repair
Peng Li1,2,3, Xiaochen Gai1,2,3, Qilin Li1,2,3
1Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.
Abstract:
Although DNA-PK inhibitors (DNA-PK-i) have been applied in clinical trials for cancer treatment, the biomarkers and mechanism of action of DNA-PK-i in tumor cell suppression remain unclear. Here, we observed that a low dose of DNA-PK-i and PARP inhibitor (PARP-i) synthetically suppresses BRCA-deficient tumor cells without inducing DNA double-strand breaks (DSBs). Instead, we found that a fraction of DNA-PK localized inside of nucleoli, where we did not observe obvious DSBs. Moreover, the Ku proteins recognize pre-rRNA that facilitates DNA-PKcs autophosphorylation independent of DNA damage. Ribosomal proteins are also phosphorylated by DNA-PK, which regulates pre-rRNA biogenesis. In addition, DNA-PK-i acts together with PARP-i to suppress pre-rRNA biogenesis and tumor cell growth. Collectively, our studies reveal a DNA damage repair-independent role of DNA-PK-i in tumor suppression.
Insights
Low doses of DNA-PK inhibitors and PARP inhibitors suppress BRCA-deficient tumors by targeting nucleolar function, not DNA damage. This reveals a novel DNA damage repair-independent mechanism for DNA-PK inhibitors in cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- DNA-PK inhibitors (DNA-PK-i) are used in cancer clinical trials, but their tumor suppression mechanisms and biomarkers are not fully understood.
- The role of DNA-PK in DNA damage repair is established, but non-canonical functions are emerging.
Purpose of the Study:
- To elucidate the mechanism of action for DNA-PK inhibitors in tumor cell suppression.
- To investigate the interplay between DNA-PK inhibitors and PARP inhibitors in BRCA-deficient cancers.
Main Methods:
- Utilized low-dose DNA-PK inhibitors and PARP inhibitors in BRCA-deficient tumor models.
- Investigated DNA double-strand breaks (DSBs) and DNA-PK localization.
- Analyzed DNA-PKcs and ribosomal protein phosphorylation.
- Assessed pre-ribosomal RNA (rRNA) biogenesis and tumor cell growth.
Main Results:
- Combined low-dose DNA-PK-i and PARP-i synergistically suppressed BRCA-deficient tumor cells without inducing DSBs.
- DNA-PK was found in nucleoli, where Ku proteins recognize pre-rRNA, promoting DNA-PKcs autophosphorylation independently of DNA damage.
- DNA-PK phosphorylates ribosomal proteins, regulating pre-rRNA biogenesis.
- Inhibition of DNA-PK and PARP suppressed pre-rRNA biogenesis and tumor cell proliferation.
Conclusions:
- DNA-PK inhibitors possess a DNA damage repair-independent role in tumor suppression.
- Targeting nucleolar function via DNA-PK and PARP inhibition offers a novel therapeutic strategy for BRCA-deficient cancers.
Related Concept Videos
Restarting Stalled Replication Forks
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Homologous Recombination
DNA Damage can Stall the Cell Cycle
Long-patch Base Excision Repair
Fixing Double-strand Breaks

